Phenotypic characteristics of B-acute Ph1-ALL
| Patient No. . | FAB Subtype . | Age/ Sex . | Level of Engraftment of NOD/SCID Mice With 10 × 106 MNCs . | % CD34+ in MNCs . | % CD34++CD38− in MNCs . | Estimated Frequency of SL-ICs/106 MNCs . |
|---|---|---|---|---|---|---|
| 1 | L2 | 16/M | 35 ± 6 | 94 | 18 | 41 |
| 2 | L2 | 34/F | 70 ± 8 | 90 | 24 | 12 |
| 3 | L1 | 42/M | 61 ± 6 | 78 | 19 | 3 |
| 4 | L2 | 24/M | 43 ± 7 | 85 | 20 | 2 |
| 5 | L1 | 37/F | 71 ± 9 | 93 | 5 | 0.2 |
| 6 | L2 | 29/M | 27 ± 8 | 94 | 21 | 9 |
| 7 | L2 | 33/M | 26 ± 6 | 84 | 26 | 19 |
| Patient No. . | FAB Subtype . | Age/ Sex . | Level of Engraftment of NOD/SCID Mice With 10 × 106 MNCs . | % CD34+ in MNCs . | % CD34++CD38− in MNCs . | Estimated Frequency of SL-ICs/106 MNCs . |
|---|---|---|---|---|---|---|
| 1 | L2 | 16/M | 35 ± 6 | 94 | 18 | 41 |
| 2 | L2 | 34/F | 70 ± 8 | 90 | 24 | 12 |
| 3 | L1 | 42/M | 61 ± 6 | 78 | 19 | 3 |
| 4 | L2 | 24/M | 43 ± 7 | 85 | 20 | 2 |
| 5 | L1 | 37/F | 71 ± 9 | 93 | 5 | 0.2 |
| 6 | L2 | 29/M | 27 ± 8 | 94 | 21 | 9 |
| 7 | L2 | 33/M | 26 ± 6 | 84 | 26 | 19 |
FAB criteria18 and NOD/SCID mice were used.
Patient Nos. 1, 2, 4, and 7 showed expression of myeloid antigens. The MNCs of all patients were transplanted at the dose indicated into 56 NOD/SCID mice using conditions previously described.
The level of human cell engraftment of the mice transplanted was determined by Southern blot analysis, using a human-specific α-satellite probe, and compared with the intensity of the bands of the human/mouse mixtures.